Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Please find enclosed a notification titled "Dr.

Reddy's to release Q4 and full year FY 23 results on May 10th, 2023 Earnings call slated for May 10th @ 7:30 PM IST / 10:00 AM EDT."

This is for your information.

For Dr. Reddy's Laboratories Limited

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Dr. Reddy's to release Q4 and full year

FY 23 results on May 10th, 2023

Earnings call slated for May 10th

@ 7:30 PM IST / 10:00 AM EDT

Hyderabad, India, April 22nd, 2023

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC:

DRREDDY) will announce results for the fourth quarter and full year ended March 31st, 2023 on Wednesday, May 10th,

2023 after the Board Meeting.

Following the release, the management of the Company

will host an earnings call to discuss the Company's financial performance. (Dial In and other details given below)

The play back will be available after the earnings

call, till May 17th, 2023. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 65827.

Conference Joining Information

Option 1: Express Join with DiamondPass

Pre-register with the below link and join without waiting for the operator.

No password/pin number is necessary to dial in to

any of the above numbers. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE:

500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in

1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good Health Can't

Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major

therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets

include - USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has

led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability

and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship;

access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future

expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known

or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or

implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will",

"should", "expects", "plans", "intends", "anticipates", "believes", "estimates",

"predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual

results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions

such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency

/ severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive

factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions

or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our,

and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other

widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with

the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"

sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information

contained herein." The company assumes no obligation to update any information contained herein.